Dr. Raymond Roos, Editor-in-Chief

Dr. Roos serves on the Scientific Advisory Board of Revalesio Corporation and a Data and Safety Monitoring Board for a clinical trial of a Mallinckrodt Pharmaceuticals product, received consulting fees from Best Doctors, and owns stock in Amgen, Merck, Ionis, and Express Scripts.